Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$1.13 - $1.62 $2,676 - $3,837
-2,369 Reduced 16.32%
12,149 $19,000
Q3 2022

Nov 14, 2022

SELL
$1.2 - $2.07 $3,277 - $5,653
-2,731 Reduced 15.83%
14,518 $18,000
Q2 2022

Aug 15, 2022

SELL
$1.86 - $2.62 $61,043 - $85,985
-32,819 Reduced 65.55%
17,249 $35,000
Q1 2022

May 16, 2022

SELL
$2.29 - $3.88 $207,906 - $352,261
-90,789 Reduced 64.45%
50,068 $125,000
Q4 2021

Feb 14, 2022

BUY
$3.43 - $4.65 $228,359 - $309,583
66,577 Added 89.63%
140,857 $525,000
Q3 2021

Nov 15, 2021

BUY
$3.1 - $4.32 $230,268 - $320,889
74,280 New
74,280 $298,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $128M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.